Literature DB >> 10451019

Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin.

S Cuzzocrea1, G Costantino, E Mazzon, A P Caputi.   

Abstract

The aim of the present study was to investigate the effect of melatonin on the production of the inflammatory mediator prostaglandins in a model of acute inflammation, carrageenan-induced pleurisy, where prostaglandins are known to play a crucial role. The results show that melatonin (12.5, 25, and 50 mg/kg, intraperitoneally, 15 min before the carrageenan) inhibits the inflammatory response (pleural exudate formation, polymorphonuclear cell infiltration, and prostaglandin production) in a dose-dependent manner. Immunohistochemical examination demonstrated a marked increase in the immunoreactivity to cyclooxygenase-2 (COX-2) in the lungs of carrageenan-treated rats. Pretreatment of carrageenan-treated rats with melatonin (50 mg/kg, intraperitoneally, 15 min before the carrageenan) prevented COX-2 expression. The present results demonstrate that melatonin exerts potent anti-inflammatory effects. Part of these anti-inflammatory effects may be related to a reduction of prostaglandin production during the inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10451019     DOI: 10.1111/j.1600-079x.1999.tb00591.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  8 in total

1.  Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding.

Authors:  Wu-Guo Deng; Shao-Tzu Tang; Hui-Ping Tseng; Kenneth K Wu
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

2.  Melatonin protects against myocardial hypertrophy induced by lipopolysaccharide.

Authors:  Qi Lu; Xin Yi; Xiang Cheng; Xiaohui Sun; Xiangjun Yang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-12-05       Impact factor: 2.416

Review 3.  The melatonin immunomodulatory actions in radiotherapy.

Authors:  M Najafi; A Shirazi; E Motevaseli; Gh Geraily; F Norouzi; M Heidari; S Rezapoor
Journal:  Biophys Rev       Date:  2017-03-27

Review 4.  Melatonin for the treatment of irritable bowel syndrome.

Authors:  Kewin Tien Ho Siah; Reuben Kong Min Wong; Khek Yu Ho
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

5.  Cognitive and neuroplasticity mechanisms by which congenital or early blindness may confer a protective effect against schizophrenia.

Authors:  Steven M Silverstein; Yushi Wang; Brian P Keane
Journal:  Front Psychol       Date:  2013-01-21

Review 6.  Sleep Deprivation and Neurological Disorders.

Authors:  Muhammed Bishir; Abid Bhat; Musthafa Mohamed Essa; Okobi Ekpo; Amadi O Ihunwo; Vishnu Priya Veeraraghavan; Surapaneni Krishna Mohan; Arehally M Mahalakshmi; Bipul Ray; Sunanda Tuladhar; Sulie Chang; Saravana Babu Chidambaram; Meena Kishore Sakharkar; Gilles J Guillemin; M Walid Qoronfleh; David M Ojcius
Journal:  Biomed Res Int       Date:  2020-11-23       Impact factor: 3.411

7.  Melatonin in antinociception: its therapeutic applications.

Authors:  Venkatramanujam Srinivasan; Edward C Lauterbach; Khek Yu Ho; Dario Acuña-Castroviejo; Rahimah Zakaria; Amnon Brzezinski
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

8.  Inhibition of Calotropis procera latex-induced inflammatory hyperalgesia by oxytocin and melatonin.

Authors:  Biswa M Padhy; Vijay L Kumar
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.